XANAX is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. It’s adverse effects are generally related to the sedation it can cause. It has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.
This product is intended for laboratory research purposes only and are not to be used for any other purposes.